PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab
injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid
tumors. It focuses on assessing the safety, tolerability, and pharmacokinetic profile of a
three-drug combination regimen comprising albumin-bound paclitaxel injection (Kealil),
paclitaxel injection (Taxol), and Fuquinitinib capsule (Aiutec, Fruquintinib).